Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Trizogen - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Trizogen

Approved

STANDARD

Trizogen

Interphil Laboratories, Inc.🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: 153e07820e346fc7
Company: Interphil Laboratories, Inc.
Type: Standard

Approval Details

Approval Id: 153e07820e346fc7
Drug Approval Philippines Name: Trizogen
Product Name: Trizogen
Registration Number: DRP-10715
Brand Name: Trizogen
Generic Name: Polymyxin B Sulfate + Bacitracin Zinc + Neomycin Sulfate
Dosage Form: Topical Ointment
Dosage Strength: 5,000 IU/650 IU/3.5 mg per gram
Manufacturer: Interphil Laboratories, Inc.
Issuance Date: 24 January 2022
Expiry Date: 11 November 2026
Classification: Over-The-Counter (OTC)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

153e07820e346fc7

Type

Standard

Back to Philippines FDA Approvals